|
View previous topic :: View next topic |
Author |
Message |
agate Site Admin
Joined: 17 May 2006 Posts: 5694 Location: Oregon
|
Posted: Wed Jul 10, 2013 11:32 am Post subject: (Abst.) Mortality in patients w/MS |
|
|
Grim. From PubMed, July 10, 2013:
Quote: |
Neurology. 2013 Jul 9;81(2):184-192.
Mortality in patients with multiple sclerosis
Scalfari A, Knappertz V, Cutter G, Goodin DS, Ashton R, Ebers GC.
From the Centre of Neuroscience (A.S.), Division of Experimental Medicine, Department of Medicine, Imperial College, Hammersmith Hospital, London, UK; Department of Neurology (V.K.), Heinrich Heine University Düsseldorf, Düsseldorf, Germany; AstraZeneca-Medimmune (V.K.), Gaithersburg, MD; Section on Research Methods and Clinical Trials (G.C.), University of Alabama at Birmingham, Birmingham; Department of Neurology (D.S.G.), University of California, San Francisco; PAREXEL MMS (R.A.), West Sussex; and Nuffield Department of Clinical Neurosciences (G.E.), John Radcliffe Hospital, University of Oxford, Oxford, UK.
Mortality in patients with multiple sclerosis (MS) is significantly increased compared with the general population. Many questions concerning survival in MS are still unanswered due to the difficulty of comparing information collected at different times and in different geographic areas. The increasing incidence of MS, the improvement in care of the chronically disabled, and different methodologies may explain the lack of coherence among studies' results. Reported times to death from birth and from disease onset/diagnosis are highly variable. Patients older at onset or with primary progressive course have shorter survival; however, data on sex and mortality are contradictory. Changes in sex ratio in MS over time represent one possible explanation.
MS is the main cause of death in ≥50% of patients and the incidence of deaths not due to MS varies among countries. Particularly, suicide is substantially increased in patients with MS, and, despite its varying incidence, mainly due to "cultural bias," it should be considered an MS-related cause of death. Recent results of the long-term follow-up study of interferon-β-1b demonstrated a significant reduction of mortality among treated patients. Notwithstanding its long latency, mortality is therefore an unambiguously valid long-term outcome in randomized controlled trials. It usefully combines the net impact of treatment efficacy on longevity and adverse events, which may reduce it.
PMID: 23836941 |
The abstract can be seen here. |
|
Back to top |
|
|
|
|
You can post new topics in this forum You can reply to topics in this forum You can edit your posts in this forum You can delete your posts in this forum You cannot vote in polls in this forum
|
|
|